ARMONK, N.Y., Aug. 13, 2026 /PRNewswire/ -- IBM (NYSE: IBM) today announced a strategic partnership with OpenAI to help enterprises deliver business outcomes by deploying AI at scale across core business operations and complex workflows, while strengthening cyber defense and resilience through programs like OpenAI Daybreak. The partnership includes joint-go-to market initiatives and creating industry-specific solutions for financial services, government, telecommunications, and retail, as well as key enterprise domains such as finance, procurement, customer operations, and HR.
The partnership embeds OpenAI frontier models like GPT-5.6 and products like Codex and ChatGPT Work into IBM Consulting Advantage, IBM's AI platform for delivering consulting services to clients, combining AI agents, industry assets, and cybersecurity capabilities to help organizations securely deploy AI at scale, drive business outcomes, and create new commercial models.
IBM will bring forward-deployed units of highly specialized engineers and consultants trained through the OpenAI Partner Network to work directly with clients to accelerate AI implementation across complex business workflows and highly regulated environments. IBM will also launch a dedicated OpenAI Practice, with thousands of consultants and engineers obtaining expert-level certifications under the OpenAI Partner Network.
Together, IBM and OpenAI aim to help organizations tackle one of the biggest barriers to scaling AI – turning decades of fragmented processes, legacy systems, and operational complexity into AI-driven operations that can be deployed even more safely and securely.
The partnership will focus on three key areas:
"While enterprises are rapidly investing in AI, they are looking for practical ways to apply it across their core operations to deliver measurable business outcomes and create new commercial models," said Andy Baldwin, Global Senior Vice President, IBM Consulting. "The challenge is not access to AI technologies — it's integrating AI securely and at scale into complex enterprise environments and workflows. By embedding OpenAI's technology with IBM Consulting's AI assets, industry solutions, and cybersecurity capabilities, we can help clients accelerate secure, AI deployments at scale."
"The organizations pulling ahead with AI are the ones turning it into a trusted part of how their business operates," said Denise Dresser, Chief Revenue Officer at OpenAI. "IBM Consulting and OpenAI are helping organizations make that shift, combining deep transformation expertise to deploy AI that is secure, operational, and aligned with real business priorities."
As part of the collaboration, IBM will join OpenAI's Elite partner tier, reflecting the companies' shared focus on delivering secure, enterprise-ready AI at scale.
Statements regarding IBM's and OpenAI's future direction and intent are subject to change or withdrawal without notice, and represent goals and objectives only.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.
Media Contact
Elizabeth.Brophy
elizabeth.brophy@ibm.com
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ibm-partners-with-openai-to-accelerate-secure-ai-deployment-for-enterprises-across-core-operations-302850349.html
Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.
Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.
Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.
Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.